These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 32911202)

  • 1. Effect of metformin and insulin combination on monocyte chemoattractant protein-1 and cathepsin-D in type 2 diabetes mellitus.
    Kher M; Beri S; Rehan HS; Prakash A; Gupta LK
    Diabetes Metab Syndr; 2020; 14(6):1703-1710. PubMed ID: 32911202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of increased levels of MCP-1 and cathepsin-D in young onset type 2 diabetes patients (T2DM-Y) with severity of diabetic retinopathy.
    Reddy S; Amutha A; Rajalakshmi R; Bhaskaran R; Monickaraj F; Rangasamy S; Anjana RM; Abhijit S; Gokulakrishnan K; Das A; Mohan V; Balasubramanyam M
    J Diabetes Complications; 2017 May; 31(5):804-809. PubMed ID: 28336215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-kB Levels in Type 2 Diabetes.
    Liu X; Huang J; Li J; Mao Q; He J
    J Coll Physicians Surg Pak; 2019 Mar; 29(3):218-221. PubMed ID: 30823945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats.
    Salman ZK; Refaat R; Selima E; El Sarha A; Ismail MA
    Eur J Pharmacol; 2013 Aug; 714(1-3):448-55. PubMed ID: 23845213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of vitamin D supplementation on circulatory YKL-40 and MCP-1 biomarkers associated with vascular diabetic complications: A randomized, placebo-controlled, double-blind clinical trial.
    Omidian M; Mahmoudi M; Javanbakht MH; Eshraghian MR; Abshirini M; Daneshzad E; Hasani H; Alvandi E; Djalali M
    Diabetes Metab Syndr; 2019; 13(5):2873-2877. PubMed ID: 31425951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Nybäck-Nakell Å; Adamson U; Lins PE; Landstedt-Hallin L
    Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Vitamin D Supplementation on Metabolic and Oxidative Stress Markers in Patients With Type 2 Diabetes: A 6-Month Follow Up Randomized Controlled Study.
    Cojic M; Kocic R; Klisic A; Kocic G
    Front Endocrinol (Lausanne); 2021; 12():610893. PubMed ID: 34489860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
    Kiyici S; Ersoy C; Kaderli A; Fazlioglu M; Budak F; Duran C; Gul OO; Sigirli D; Baran I; Tuncel E; Erturk E; Imamoglu S
    Diabetes Res Clin Pract; 2009 Oct; 86(1):44-50. PubMed ID: 19674806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.
    Charpentier G; Fleury F; Kabir M; Vaur L; Halimi S
    Diabet Med; 2001 Oct; 18(10):828-34. PubMed ID: 11678974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA expression in newly diagnosed diabetes subclinical vascular lesions.
    Fang ZH; Liu Y; Bao TT; Ni YQ; Liu J; Shi GB; Wu JP; Yang JP; Zhang H
    World J Gastroenterol; 2013 May; 19(19):2963-8. PubMed ID: 23704830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Fan YP; Wu CT; Lin JL; Hsiung CA; Liu HY; Lai JN; Yang CC
    J Diabetes Res; 2020; 2020():9161039. PubMed ID: 32377525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I; El Kafrawy N; Raouf R; Yousry D
    Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial.
    Nordklint AK; Almdal TP; Vestergaard P; Lundby-Christensen L; Boesgaard TW; Breum L; Gade-Rasmussen B; Sneppen SB; Gluud C; Hemmingsen B; Jensen T; Krarup T; Madsbad S; Mathiesen ER; Perrild H; Tarnow L; Thorsteinsson B; Vestergaard H; Lund SS; Eiken P
    Osteoporos Int; 2018 Nov; 29(11):2517-2526. PubMed ID: 30027438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.